CANDEL THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
CANDEL THERAPEUTICS, INC. (CADL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $5.46 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $6.49, a 5.53% increase year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $6.15, a 79.82% increase year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.42, a 19.53% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $4.25.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $6.25, a 86.01% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $3.36, a 29.23% increase from fiscal 2023.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $2.60, a 25.29% decline from fiscal 2022.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $3.48, a 124.52% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.46 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $6.49 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $6.25 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $6.07 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $6.06 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $6.15 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $3.36 10-K · filed 2025-03-13 | |||
| 2024-09-30 | $3.36 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $3.39 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $3.42 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $2.60 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $2.58 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $3.43 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $4.25 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $3.48 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $3.97 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $4.19 10-Q · filed 2022-08-05 | |||
| 2021-12-31 | $1.55 10-K · filed 2022-03-29 | |||
| 2021-09-30 | $1.55 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $1.55 10-Q · filed 2021-09-08 | |||
| 2020-12-31 | $1.46 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |